Waddill William D.'s Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Dec 18, 2024
- Accession no.
- 0001628280-24-051925
- Filed
- Dec 18, 2024
- Trade date
- Dec 16-17, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $164.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Waddill William D.CIK 0001553338 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 16, 2024 | Common Stock | SSaleDisposed | −3,748 | $21.90 | −$82,081.2 | 44,125 | Direct | |
| Dec 17, 2024 | Common Stock | SSaleDisposed | −3,747 | $22.04 | −$82,583.88 | 40,378 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.